Evidence map›Paper›PMID 29665007›Full record

ArticleJournal of cellular physiology2018

Protective effect of miR378* on doxorubicin-induced cardiomyocyte injury via calumenin.

Yu Wang, Xiaoxue Cui, Yilin Wang, Yao Fu, Xin Guo, Jie Long, Chengxi Wei, Ming Zhao

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Recent Advances in Gene Therapy for Cardiac Tissue Regeneration.International journal of molecular sciences · 2021
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yu WangMedicinal Chemistry and Pharmacology Institute, Inner Mongolia University for Nationalities, Tongliao, Inner Mongolia, P.R. China.
Xiaoxue CuiAffiliated Hospital of Inner Mongolia University for Nationalities, Tongliao, Inner Mongolia, P.R. China.
Yilin WangAffiliated Hospital of Inner Mongolia University for Nationalities, Tongliao, Inner Mongolia, P.R. China.
Yao FuMedicinal Chemistry and Pharmacology Institute, Inner Mongolia University for Nationalities, Tongliao, Inner Mongolia, P.R. China.
Xin GuoMedicinal Chemistry and Pharmacology Institute, Inner Mongolia University for Nationalities, Tongliao, Inner Mongolia, P.R. China.
Jie LongAffiliated Hospital of Inner Mongolia University for Nationalities, Tongliao, Inner Mongolia, P.R. China.
Chengxi WeiMedicinal Chemistry and Pharmacology Institute, Inner Mongolia University for Nationalities, Tongliao, Inner Mongolia, P.R. China.
Ming ZhaoAffiliated Hospital of Inner Mongolia University for Nationalities, Tongliao, Inner Mongolia, P.R. China.ORCID 0000-0002-7383-9398
Inner Mongolia University for Nationalities · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (Dox) is a highly effective antitumor antibiotic, however myocardial toxicity severely limits its use clinically. The pathogenesis of doxorubicin-induced cardiomyopathy is unclear. In Dox cardiomyopathy mice, there is a decline in cardiac function, a change in myocardial pathology and a reduction in miR378* expression. Expression changes in calumenin, an endoplasmic reticulum stress (ERS) chaperone protein and pathway factor, as well as apoptosis, were observed in cardiomyocytes after doxorubicin-induced injury. However, miR378* increased calumenin expression, eased ERS, and reduced cardiomyocyte apoptosis, while, silencing miR378* reduced calumenin expression, aggravated ERS, and increased cardiomyocyte apoptosis. The above results indicate that miR378* alleviates ERS and inhibits the activation of the ERS-mediated apoptosis signaling pathway in cardiomyocytes via regulating calumenin expression, thereby reducing cardiomyocyte apoptosis after doxorubicin-induced injury. Increasing miR378* expression may be a new way to improve cardiac function and quality of life in patients with Dox cardiomyopathy.

Indexed as

AnimalsAnimals, NewbornApoptosisCalcium-Binding ProteinsCardiomyopathiesDoxorubicinEndoplasmic Reticulum StressGene Expression RegulationHeart InjuriesHumansMicroRNAsMyocardiumMyocytes, CardiacNeoplasmsOrgan Culture TechniquesRatsCalcium-Binding ProteinsCALU protein, humanDoxorubicinMicroRNAsMIRN378 microRNA, humanapoptosiscalumenindoxorubicinERSmiR378*

Identifiers

PMID29665007
PMCPMC6055600
OpenAlexW2801561382

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.